Showing results (41-50 of 175) with videos related to
Sort By:
Pageof 18
Current Hematologic Malignancy Reports|August 6, 2016
Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSMNaveen Pemmaraju, Audun Utengen, Vikas Gupta, et al.Current Hematologic Malignancy Reports|November 7, 2017
Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2 Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media-#MPNSMNaveen Pemmaraju, Audun Utengen, Vikas Gupta, et al.BMC Complementary and Alternative Medicine|June 9, 2019
Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future researchJennifer Huberty, Ryan Eckert, Amylou Dueck, et al.JMIR Research Protocols|July 1, 2022
Insomnia as an Unmet Need in Patients With Chronic Hematological Cancer: Protocol for a Randomized Controlled Trial Evaluating a Consumer-Based Meditation App for Treatment of Sleep DisturbanceJennifer Huberty, Nishat Bhuiyan, Ryan Eckert, et al.Expert Review of Hematology|October 3, 2013
Practical management of patients with myelofibrosis receiving ruxolitinibClaire Harrison, Ruben Mesa, David Ross, et al.Leukemia & Lymphoma|September 3, 2011
Association between quality of life and clinical parameters in patients with myeloproliferative neoplasmsPeter Johansson, Ruben Mesa, Robyn Scherber, et al.Cancers|December 17, 2024
Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of MomelotinibHaifa Kathrin Al-Ali, Andrew T Kuykendall, Catherine E Ellis, et al.BMC Cancer|April 15, 2018
Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs surveyJingbo Yu, Shreekant Parasuraman, Dilan Paranagama, et al.Journal of Experimental Pharmacology|August 31, 2016
Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitorJack W Singer, Suliman Al-Fayoumi, Haiching Ma, et al.Blood Advances|December 4, 2020
Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burdenDouglas Tremblay, Ruben Mesa, Bart Scott, et al.Pageof 18